These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

578 related articles for article (PubMed ID: 33203679)

  • 1. Targeting the renin-angiotensin signaling pathway in COVID-19: Unanswered questions, opportunities, and challenges.
    Sriram K; Loomba R; Insel PA
    Proc Natl Acad Sci U S A; 2020 Nov; 117(47):29274-29282. PubMed ID: 33203679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renin-angiotensin system at the interface of COVID-19 infection.
    Gul R; Kim UH; Alfadda AA
    Eur J Pharmacol; 2021 Jan; 890():173656. PubMed ID: 33086029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin II receptors: Impact for COVID-19 severity.
    Aksoy H; Karadag AS; Wollina U
    Dermatol Ther; 2020 Nov; 33(6):e13989. PubMed ID: 32645228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update.
    Shukla AK; Banerjee M
    High Blood Press Cardiovasc Prev; 2021 Mar; 28(2):129-139. PubMed ID: 33635533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers.
    Danser AHJ; Epstein M; Batlle D
    Hypertension; 2020 Jun; 75(6):1382-1385. PubMed ID: 32208987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disequilibrium between the classic renin-angiotensin system and its opposing arm in SARS-CoV-2-related lung injury.
    Sarzani R; Giulietti F; Di Pentima C; Giordano P; Spannella F
    Am J Physiol Lung Cell Mol Physiol; 2020 Aug; 319(2):L325-L336. PubMed ID: 32639866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drugs acting on renin angiotensin system and use in ill patients with COVID-19.
    Alexandre J; Cracowski JL; Richard V; Bouhanick B;
    Therapie; 2020; 75(4):319-325. PubMed ID: 32553503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential Implications of Angiotensin-converting Enzyme 2 Blockades on Neuroinflammation in SARS-CoV-2 Infection.
    Paul D; Mohankumar SK; Thomas RS; Kheng CB; Basavan D
    Curr Drug Targets; 2022; 23(4):364-372. PubMed ID: 34732115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Actions of Novel Angiotensin Receptor Blocking Drugs, Bisartans, Relevant for COVID-19 Therapy: Biased Agonism at Angiotensin Receptors and the Beneficial Effects of Neprilysin in the Renin Angiotensin System.
    Moore GJ; Ridgway H; Kelaidonis K; Chasapis CT; Ligielli I; Mavromoustakos T; Bojarska J; Matsoukas JM
    Molecules; 2022 Jul; 27(15):. PubMed ID: 35956801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19 Therapeutics Why Not Angiotensin Receptor Blockers (ARBs)?
    Hariharan TS
    J Assoc Physicians India; 2023 Nov; 71(11):71-75. PubMed ID: 38720500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin converting enzyme 2 at the interface between renin-angiotensin system inhibition and coronavirus disease 2019.
    Siri-Angkul N; Chattipakorn SC; Chattipakorn N
    J Physiol; 2020 Oct; 598(19):4181-4195. PubMed ID: 32710575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19, Angiotensin-Converting Enzyme 2 and Renin-Angiotensin System Inhibition: Implications for Practice.
    Katsi V; Pavlidis G; Charalambous G; Tousoulis D; Toutouzas K
    Curr Hypertens Rev; 2022; 18(1):3-10. PubMed ID: 33475077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients.
    Rossi GP; Sanga V; Barton M
    Elife; 2020 Apr; 9():. PubMed ID: 32250244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A hypothesis for pathobiology and treatment of COVID-19: The centrality of ACE1/ACE2 imbalance.
    Sriram K; Insel PA
    Br J Pharmacol; 2020 Nov; 177(21):4825-4844. PubMed ID: 32333398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renin-angiotensin system inhibitors in management of hypertension during the COVID-19 pandemic.
    Dworakowska D; Grossman AB
    J Physiol Pharmacol; 2020 Apr; 71(2):. PubMed ID: 32633235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacovigilance in patients with diabetes: A data-driven analysis identifying specific RAS antagonists with adverse pulmonary safety profiles that have implications for COVID-19 morbidity and mortality.
    Stafford EG; Riviere JE; Xu X; Kawakami J; Wyckoff GJ; Jaberi-Douraki M
    J Am Pharm Assoc (2003); 2020; 60(6):e145-e152. PubMed ID: 32561317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Renin-Angiotensin System, Hypertension, and SARS-CoV-2 Infection: a Review.
    Gathiram P; Mackraj I; Moodley J
    Curr Hypertens Rep; 2021 Mar; 23(4):17. PubMed ID: 33768439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19.
    Cheng H; Wang Y; Wang GQ
    J Med Virol; 2020 Jul; 92(7):726-730. PubMed ID: 32221983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of renin angiotensin blockers on angiotensin converting enzyme 2 level in cardiovascular patients.
    Farid Fahmy S; El Derany MO; Khorshid H; Saleh A; El-Demerdash E
    BMC Pharmacol Toxicol; 2023 Apr; 24(1):24. PubMed ID: 37060024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.